MA52003A - Procédés de traitement de maladies associées au hpv - Google Patents

Procédés de traitement de maladies associées au hpv

Info

Publication number
MA52003A
MA52003A MA052003A MA52003A MA52003A MA 52003 A MA52003 A MA 52003A MA 052003 A MA052003 A MA 052003A MA 52003 A MA52003 A MA 52003A MA 52003 A MA52003 A MA 52003A
Authority
MA
Morocco
Prior art keywords
hpv
diseases associated
treatment methods
diseases
treatment
Prior art date
Application number
MA052003A
Other languages
English (en)
Inventor
Howard Bernstein
Katarina Blagovic
Matt Booty
Kelan Hlavaty
Scott Loughhead
Melissa Myint
Armon R Sharei
Lee Ann Talarico
Alfonso Vicente-Suarez
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of MA52003A publication Critical patent/MA52003A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA052003A 2018-03-12 2019-03-11 Procédés de traitement de maladies associées au hpv MA52003A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641988P 2018-03-12 2018-03-12
US201962794517P 2019-01-18 2019-01-18
US201962812225P 2019-02-28 2019-02-28

Publications (1)

Publication Number Publication Date
MA52003A true MA52003A (fr) 2021-01-20

Family

ID=65904594

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052003A MA52003A (fr) 2018-03-12 2019-03-11 Procédés de traitement de maladies associées au hpv

Country Status (18)

Country Link
US (1) US20210038709A1 (fr)
EP (1) EP3765073A2 (fr)
JP (1) JP2021517895A (fr)
KR (1) KR20200130371A (fr)
CN (1) CN112105383A (fr)
AU (1) AU2019234549B2 (fr)
BR (1) BR112020018609A2 (fr)
CA (1) CA3093826A1 (fr)
CO (1) CO2020012583A2 (fr)
CR (1) CR20200461A (fr)
IL (1) IL277190B1 (fr)
MA (1) MA52003A (fr)
MX (1) MX2020009441A (fr)
PE (1) PE20201201A1 (fr)
PH (1) PH12020551437A1 (fr)
SG (1) SG11202008863XA (fr)
TW (1) TW202003025A (fr)
WO (1) WO2019178005A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
RU2770492C2 (ru) 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биологических молекул для индуцирования толерантности
AU2019234550B2 (en) * 2018-03-12 2025-12-04 Sqz Biotechnologies Company Intracellular delivery of biomolecules to modify immune response
CN114127267A (zh) * 2019-02-28 2022-03-01 Sqz生物技术公司 向pbmc递送生物分子以改变免疫应答
AU2020271040B2 (en) 2019-04-08 2025-07-03 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
CA3140029A1 (fr) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Methodes, systemes et dispositifs de selection de patient tl1a
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用
CN110846318A (zh) * 2019-11-29 2020-02-28 华中科技大学同济医学院附属同济医院 治疗hpv感染的纳米粒制剂中新的靶向序列以及新pbae的制备方法
IL298038A (en) 2020-05-11 2023-01-01 Hoffmann La Roche Combination therapy with modified pbmcs and an immunoconjugate
WO2022017217A1 (fr) * 2020-07-24 2022-01-27 四川大学华西医院 Vaccin allogénique à lymphocytes b ciblant veb et son procédé de préparation
KR20230058388A (ko) 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 무핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법
US20250255961A1 (en) 2020-07-29 2025-08-14 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using nucleated cells
US20230263879A1 (en) * 2020-09-02 2023-08-24 Sqz Biotechnologies Company Methods to stimulate hla-agnostic immune responses to proteins using nucleated cells
WO2022147026A1 (fr) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Procédés pour le traitement de cancers avec des pbmc modifiées
US20220296691A1 (en) * 2020-12-29 2022-09-22 Sqz Biotechnologies Company Methods for treating cancer with activating antigen carriers
CA3203709A1 (fr) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations d'activation de porteurs d'antigene
WO2022147017A1 (fr) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations pour la cryoconservation de pbmc
EP4377447A1 (fr) 2021-07-29 2024-06-05 SQZ Biotechnologies Company Procédés pour générer des lymphocytes infiltrant les tumeurs améliorés par administration microfluidique
US20250043244A1 (en) 2021-11-11 2025-02-06 Stemcell Technologies Canada Inc. Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023196884A1 (fr) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Dosage pour la détection du papillomavirus humain (vph) de type 16 (hpv-16)
EP4561615A2 (fr) 2022-07-28 2025-06-04 Stemcell Technologies Canada Inc. Formulations de cellules présentatrices d'antigène améliorées
CA3262756A1 (fr) 2022-07-28 2024-02-01 Stemcell Technologies Canada Inc. Méthodes de traitement du cancer avec des cellules présentatrices d'antigène améliorées

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
AU2008269721B2 (en) * 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
EP2429585B1 (fr) * 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Immunothérapie par vaccin
CN103987836B (zh) 2011-10-17 2018-04-10 麻省理工学院 细胞内传递
CA2918216C (fr) * 2013-07-15 2023-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteurs de lymphocytes t anti-papillomavirus humain 16 e6
RU2739794C2 (ru) * 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
DK3215187T3 (en) * 2014-11-04 2018-12-10 Janssen Vaccines & Prevention Bv THERAPEUTIC HPV16 VACCINES
WO2017041050A1 (fr) * 2015-09-04 2017-03-09 Sqz Biotechnologies Company Administration intracellulaire de biomolécules médiée par une surface présentant des pores
CN116218916A (zh) * 2016-01-12 2023-06-06 Sqz生物技术公司 复合物的细胞内递送
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用

Also Published As

Publication number Publication date
JP2021517895A (ja) 2021-07-29
WO2019178005A3 (fr) 2019-10-17
US20210038709A1 (en) 2021-02-11
RU2020132524A (ru) 2022-04-13
KR20200130371A (ko) 2020-11-18
IL277190B1 (en) 2025-12-01
SG11202008863XA (en) 2020-10-29
CR20200461A (es) 2021-03-11
PE20201201A1 (es) 2020-11-11
IL277190A (en) 2020-10-29
EP3765073A2 (fr) 2021-01-20
PH12020551437A1 (en) 2021-09-06
AU2019234549B2 (en) 2026-02-12
MX2020009441A (es) 2021-01-08
TW202003025A (zh) 2020-01-16
WO2019178005A2 (fr) 2019-09-19
AU2019234549A1 (en) 2020-10-08
CA3093826A1 (fr) 2019-09-19
CO2020012583A2 (es) 2020-10-30
BR112020018609A2 (pt) 2020-12-29
CN112105383A (zh) 2020-12-18

Similar Documents

Publication Publication Date Title
MA52003A (fr) Procédés de traitement de maladies associées au hpv
EP3463577A4 (fr) Compositions et procédés de traitement de maladies associées au papillomavirus humain (pvh)
EP3661955A4 (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA50056A (fr) Procédés de traitement de tumeur
EP3426250A4 (fr) Procédés de traitement
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3601536A4 (fr) Procédés de traitement
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
EP3548039A4 (fr) Méthodes de traitement de maladies associées au stress mitochondrial
EP3752180A4 (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3288565A4 (fr) Composition de matrice extracellulaire pour le traitement du cancer ou des maladies immunologiques
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3749064A4 (fr) Machine de traitement au plasma
EP3347492A4 (fr) Procédés pour le diagnostic histologique et le traitement de maladies
EP3630101A4 (fr) Méthodes de traitement de maladies
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3592224A4 (fr) Méthode permettant de surveiller le traitement de maladies neuropsychiatriques
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP4017349A4 (fr) Appareil thérapeutique